469 related articles for article (PubMed ID: 3567926)
1. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
3. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
Mulcahy RT; Siemann DW
Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
[TBL] [Abstract][Full Text] [Related]
4. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW
Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968
[TBL] [Abstract][Full Text] [Related]
5. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
6. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
7. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
8. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
9. [Disruption of DNA synthesis and structure of mouse L1210 leukemia cells, sensitive and resistant to 1-methyl-1 nitrosourea and 1,3-bis(2-chloroethyl)-1-nitrosourea in vivo].
Kukushkina GV; Peretolchina NM; Minenkova EA; Verovskiĭ VN; Sof'ina ZP
Biokhimiia; 1984 Jul; 49(7):1189-98. PubMed ID: 6477985
[TBL] [Abstract][Full Text] [Related]
10. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
Schmid FA; Otter GM; Stock CC
Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
[TBL] [Abstract][Full Text] [Related]
11. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
12. Drug sensitivity of methylnitrosourea- and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea-resistant L1210 lines.
Schmid FA; Otter GM; Chen CF
Cancer Res; 1986 Sep; 46(9):4469-71. PubMed ID: 3731103
[TBL] [Abstract][Full Text] [Related]
13. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
15. Patterns of resistance and therapeutic synergism among alkylating agents.
Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
17. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
18. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay.
Tofilon PJ; Basic I; Milas L
Cancer Res; 1985 May; 45(5):2025-30. PubMed ID: 4039220
[TBL] [Abstract][Full Text] [Related]
19. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
[TBL] [Abstract][Full Text] [Related]
20. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
